There was also a statistically significant association between GLP-1 RA use and a lower risk of MACE, non-fatal myocardial infarction, and all-cause death, consistently with CVOTs, but we reported higher event rates as expected in a real-world population.14 Interestingly, we found an interaction between ischaemic heart disease and GLP-1 RA use for the association with CV mortality or HF hospitalization, with a lower risk in those receiving the treatment if they did not have a history of ischemic heart disease. This evidence concerns the gene GLP1R and heart disorder.